Zacks Research Reduces Earnings Estimates for AngioDynamics

Posted by Brenda Bartman on Aug 6th, 2026

AngioDynamics, Inc. (NASDAQ:ANGO – Free Report) – Research analysts at Zacks Research decreased their Q1 2027 earnings per share estimates for shares of AngioDynamics in a research report issued on Tuesday, August 4th. Zacks Research analyst Team now expects that the medical instruments supplier will earn ($0.09) per share for the quarter, down from their previous estimate of ($0.07). Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for AngioDynamics’ current full-year earnings is ($0.27) per share. Zacks Research also issued estimates for AngioDynamics’ Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.02) EPS, FY2027 earnings at ($0.24) EPS, Q1 2028 earnings at ($0.06) EPS, Q2 2028 earnings at ($0.07) EPS, Q4 2028 earnings at ($0.04) EPS and FY2028 earnings at ($0.17) EPS.

A number of other research analysts also recently issued reports on the stock. HC Wainwright upped their target price on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a report on Friday, July 17th. Finally, Canaccord Genuity Group lifted their target price on shares of AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $19.50.

Read Our Latest Report on ANGO

AngioDynamics Stock Down 1.0%

AngioDynamics stock opened at $15.04 on Thursday. The business’s 50-day simple moving average is $13.01 and its 200 day simple moving average is $11.61. The stock has a market cap of $621.60 million, a price-to-earnings ratio of -17.29 and a beta of 0.33. AngioDynamics has a 12-month low of $8.36 and a 12-month high of $15.41.

AngioDynamics (NASDAQ:ANGO – Get Free Report) last announced its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. The firm had revenue of $86.61 million for the quarter, compared to analyst estimates of $80.24 million. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS.

Insider Buying and Selling at AngioDynamics

In related news, SVP Warren Nighan, Jr. sold 23,370 shares of AngioDynamics stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the transaction, the senior vice president owned 64,745 shares of the company’s stock, valued at $953,046.40. This trade represents a 26.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 6.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On AngioDynamics

Hedge funds have recently bought and sold shares of the company. Farther Finance Advisors LLC grew its holdings in shares of AngioDynamics by 146.4% in the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 1,199 shares during the period. Kemnay Advisory Services Inc. acquired a new position in AngioDynamics in the fourth quarter valued at about $27,000. State of Wyoming acquired a new position in AngioDynamics in the second quarter valued at about $31,000. Russell Investments Group Ltd. increased its holdings in shares of AngioDynamics by 329.5% in the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 3,213 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of AngioDynamics by 359.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock worth $54,000 after purchasing an additional 4,268 shares during the period. 89.43% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

Positive Sentiment: Zacks raised its fourth-quarter fiscal 2027 EPS forecast modestly to a loss of $0.02 from a loss of $0.03, indicating some improvement in that quarter’s outlook.
Neutral Sentiment: Brokerages collectively maintain a consensus recommendation of “Hold” for AngioDynamics, providing a less bearish view than Zacks’ rating. AngioDynamics Given Consensus Recommendation of Hold by Brokerages
Negative Sentiment: Zacks reduced its fiscal 2027 EPS forecast to a loss of $0.24 from a loss of $0.13. Estimates for the first three quarters were also cut, including Q3 2027 from a profit of $0.02 per share to a loss of $0.05.
Negative Sentiment: Longer-term expectations weakened substantially: fiscal 2028 EPS was lowered to a loss of $0.17 from a loss of $0.04, while estimates for Q1 and Q2 fiscal 2028 were reduced to losses of $0.06 and $0.07, respectively.
Negative Sentiment: Zacks also cut its Q3 2028 estimate from a profit of $0.03 to a loss of $0.01, while forecasting a fiscal 2029 loss of $0.15. The repeated downward revisions reinforce concerns about AngioDynamics’ path to profitability.

About AngioDynamics

(Get Free Report)

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.